Skip to main content
Top
Published in: Endocrine 2/2018

01-11-2018 | Mini Review

Water intake keeps type 2 diabetes away? Focus on copeptin

Authors: Giovanna Muscogiuri, Luigi Barrea, Giuseppe Annunziata, Martina Vecchiarini, Francesco Orio, Carolina Di Somma, Annamaria Colao, Silvia Savastano

Published in: Endocrine | Issue 2/2018

Login to get access

Abstract

Introduction

In both diabetic subjects and animal models high levels of vasopressin (AVP) have beendetected. The relationship between AVP and glucose metabolism is mediated through several direct andindirect effects and most of them are still unknown.

Methods

We have reviewed 100 manuscripts retrieved from Cochrane Library, Embase and Pubmeddatabases in order to highlight a possible relationship between copeptin and type 2 diabetes and to provideinsights on the molecular mechanism that could explain this association.

Results and conclusions

AVP potentiates CRH action at pituitary level resulting in an increased ACTH secretion and in turn in an increased cortisol secretion that escapes the negative feedback loop. Further, AVP regulates insulin and glucagon secretion through V1b receptor and promotes hepatic glycogenolysis and gluconeogenesis through V1a receptor. In addition to worsen glucose metabolism, AVP has been reported to have a role in the pathogenesis of diabetic complications such as cardiovascular diseases, kidney and ocular complications. Due to the very low concentration of AVP in the blood, the small size and poor stability, the assay of AVP is very difficult to perform. Thus, copeptin, the stable C-terminal portion of the prepro-vasopressin peptide has been identified as an easier assay to be measured and that mirrors AVP activity. Although there are promising evidence that copeptin could be involved in the pathogenesis of type 2 diabetes, further studies need to demonstrate the importance of copeptin as clinical marker to predict glucose metabolism derangements.
Literature
1.
go back to reference R. Roussel, L. Fezeu, N. Bouby, B. Balkau, O. Lantieri, F. Alhenc-Gelas, M. Marre, L. Bankir, D.E.S.I.R. Study Group Low water intake and risk for new-onset hyperglycemia. Diabetes Care 34, 2551–2554 (2011)CrossRef R. Roussel, L. Fezeu, N. Bouby, B. Balkau, O. Lantieri, F. Alhenc-Gelas, M. Marre, L. Bankir, D.E.S.I.R. Study Group Low water intake and risk for new-onset hyperglycemia. Diabetes Care 34, 2551–2554 (2011)CrossRef
2.
go back to reference C. Taveau, C. Chollet, L. Waeckel, D. Desposito, D.G. Bichet, M.F. Arthus, C. Magnan, E. Philippe, V. Paradis, F. Foufelle, I. Hainault, S. Enhorning, G. Velho, R. Roussel, L. Bankir, O. Melander, N. Bouby, Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats. Diabetologia 58, 1081–1090 (2015)CrossRef C. Taveau, C. Chollet, L. Waeckel, D. Desposito, D.G. Bichet, M.F. Arthus, C. Magnan, E. Philippe, V. Paradis, F. Foufelle, I. Hainault, S. Enhorning, G. Velho, R. Roussel, L. Bankir, O. Melander, N. Bouby, Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats. Diabetologia 58, 1081–1090 (2015)CrossRef
3.
go back to reference G.L. Robertson, Thirst and vasopressin function in normal and disordered states of water balance. J. Lab. Clin. Med. 101, 351–371 (1983)PubMed G.L. Robertson, Thirst and vasopressin function in normal and disordered states of water balance. J. Lab. Clin. Med. 101, 351–371 (1983)PubMed
4.
go back to reference D.A. Hems, L.M. Rodrigues, P.D. Whitton, Rapid stimulation by vasopressin, oxytocin and angiotensin II of glycogen degradation in hepatocyte suspensions. Biochem. J. 172, 311–317 (1978)CrossRef D.A. Hems, L.M. Rodrigues, P.D. Whitton, Rapid stimulation by vasopressin, oxytocin and angiotensin II of glycogen degradation in hepatocyte suspensions. Biochem. J. 172, 311–317 (1978)CrossRef
5.
go back to reference P.D. Whitton, L.M. Rodrigues, D.A. Hems, Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspension. Biochem. J. 176, 893–898 (1978)CrossRef P.D. Whitton, L.M. Rodrigues, D.A. Hems, Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspension. Biochem. J. 176, 893–898 (1978)CrossRef
6.
go back to reference E.A. Abu-Basha, S. Yibchok-Anun, W.H. Hsu, Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas. Metabolism 51, 1184–1190 (2002)CrossRef E.A. Abu-Basha, S. Yibchok-Anun, W.H. Hsu, Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas. Metabolism 51, 1184–1190 (2002)CrossRef
7.
go back to reference T. Aoyagi, J. Birumachi, M. Hiroyama, Y. Fujiwara, A. Sanbe, J. Yamauchi, A. Tanoue, Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology 148, 2075–2084 (2007)CrossRef T. Aoyagi, J. Birumachi, M. Hiroyama, Y. Fujiwara, A. Sanbe, J. Yamauchi, A. Tanoue, Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology 148, 2075–2084 (2007)CrossRef
8.
go back to reference Y. Fujiwara, M. Hiroyama, A. Sanbe, T. Aoyagi, J. Birumachi, J. Yamauchi, G. Tsujimoto, A. Tanoue, Insulin hypersensitivity in mice lacking the V1b vasopressin receptor. J. Physiol. 584, 235–244 (2007)CrossRef Y. Fujiwara, M. Hiroyama, A. Sanbe, T. Aoyagi, J. Birumachi, J. Yamauchi, G. Tsujimoto, A. Tanoue, Insulin hypersensitivity in mice lacking the V1b vasopressin receptor. J. Physiol. 584, 235–244 (2007)CrossRef
9.
go back to reference K. Nakamura, T. Aoyagi, M. Hiroyama, S. Kusakawa, R. Mizutani, A. Sanbe, J. Yamauchi, M. Kamohara, K. Momose, A. Tanoue, Both V(1A) and V(1B) vasopressin receptors deficiency result in impaired glucose tolerance. Eur. J. Pharmacol. 613, 182–188 (2009)CrossRef K. Nakamura, T. Aoyagi, M. Hiroyama, S. Kusakawa, R. Mizutani, A. Sanbe, J. Yamauchi, M. Kamohara, K. Momose, A. Tanoue, Both V(1A) and V(1B) vasopressin receptors deficiency result in impaired glucose tolerance. Eur. J. Pharmacol. 613, 182–188 (2009)CrossRef
10.
go back to reference R.L. Zerbe, F. Vinicor, G.L. Robertson, Plasma vasopressin in uncontrolled diabetes mellitus. Diabetes 28, 503–508 (1979)CrossRef R.L. Zerbe, F. Vinicor, G.L. Robertson, Plasma vasopressin in uncontrolled diabetes mellitus. Diabetes 28, 503–508 (1979)CrossRef
11.
go back to reference D.P. Brooks, D.F. Nutting, J.T. Crofton, L. Share, Vasopressin in rats with genetic and streptozocin-induced diabetes. Diabetes 38, 54–57 (1989)CrossRef D.P. Brooks, D.F. Nutting, J.T. Crofton, L. Share, Vasopressin in rats with genetic and streptozocin-induced diabetes. Diabetes 38, 54–57 (1989)CrossRef
12.
go back to reference S.S. Yi, I.K. Hwang, Y.N. Kim, I.Y. Kim, S.I. Pak, I.S. Lee, J.K. Seong, Y.S. Yoon, Enhanced expression of arginine vasopressin (Avp) in the hypothalamic paraventricular and supraoptic nuclei of type 2 diabetic rats. Neurochem. Res. 33, 833–841 (2008)CrossRef S.S. Yi, I.K. Hwang, Y.N. Kim, I.Y. Kim, S.I. Pak, I.S. Lee, J.K. Seong, Y.S. Yoon, Enhanced expression of arginine vasopressin (Avp) in the hypothalamic paraventricular and supraoptic nuclei of type 2 diabetic rats. Neurochem. Res. 33, 833–841 (2008)CrossRef
13.
go back to reference N.G. Morgenthaler, J. Struck, C. Alonso, A. Bergmann, Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin. Chem. 52, 112–119 (2006)CrossRef N.G. Morgenthaler, J. Struck, C. Alonso, A. Bergmann, Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin. Chem. 52, 112–119 (2006)CrossRef
14.
go back to reference S. Balanescu, P. Kopp, M.B. Gaskill, N.G. Morgenthaler, C. Schindler, J. Rutishauser, Correlation of plasma copeptin and vasopressin concentration in hypo-, iso-, and hyperosmolar states. J. Clin. Endocrinol. Metab. 96, 1046–1052 (2011)CrossRef S. Balanescu, P. Kopp, M.B. Gaskill, N.G. Morgenthaler, C. Schindler, J. Rutishauser, Correlation of plasma copeptin and vasopressin concentration in hypo-, iso-, and hyperosmolar states. J. Clin. Endocrinol. Metab. 96, 1046–1052 (2011)CrossRef
15.
go back to reference U. Saleem, M. Khaleghi, N.G. Morgenthaler, A. Bergmann, J. Struck, T.H. Mosley Jr., I.J. Kullo, Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. J. Clin. Endocrinol. Metab. 94, 2558–2564 (2009)CrossRef U. Saleem, M. Khaleghi, N.G. Morgenthaler, A. Bergmann, J. Struck, T.H. Mosley Jr., I.J. Kullo, Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. J. Clin. Endocrinol. Metab. 94, 2558–2564 (2009)CrossRef
16.
go back to reference F.X. Zhu, H.L. Wu, K.S. Tu, J.X. Chen, M. Zhang, C. Shi, Serum levels of copeptin are associated with type 2 diabetes and diabetic complications in Chinese population. J. Diabetes Complicat. 30, 1566–1570 (2016)CrossRef F.X. Zhu, H.L. Wu, K.S. Tu, J.X. Chen, M. Zhang, C. Shi, Serum levels of copeptin are associated with type 2 diabetes and diabetic complications in Chinese population. J. Diabetes Complicat. 30, 1566–1570 (2016)CrossRef
17.
go back to reference O. Melander, Vasopressin, from regulator to disease predictor for diabetes and cardiometabolic risk. Ann. Nutr. Metab. 68(Suppl 2), 24–28 (2016)CrossRef O. Melander, Vasopressin, from regulator to disease predictor for diabetes and cardiometabolic risk. Ann. Nutr. Metab. 68(Suppl 2), 24–28 (2016)CrossRef
18.
go back to reference S. Enhörning, T.J. Wang, P.M. Nilsson, P. Almgren, B. Hedblad, G. Berglund, J. Struck, N.G. Morgenthaler, A. Bergmann, E. Lindholm, L. Groop, V. Lyssenko, M. Orho-Melander, C. Newton-Cheh, O. Melander, Plasma copeptin and the risk of diabetes mellitus. Circulation 121, 2102–2108 (2010)CrossRef S. Enhörning, T.J. Wang, P.M. Nilsson, P. Almgren, B. Hedblad, G. Berglund, J. Struck, N.G. Morgenthaler, A. Bergmann, E. Lindholm, L. Groop, V. Lyssenko, M. Orho-Melander, C. Newton-Cheh, O. Melander, Plasma copeptin and the risk of diabetes mellitus. Circulation 121, 2102–2108 (2010)CrossRef
19.
go back to reference V. Salomaa, A. Havulinna, O. Saarela, T. Zeller, P. Jousilahti, A. Jula, T. Muenzel, A. Aromaa, A. Evans, K. Kuulasmaa, S. Blankenberg, Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS ONE 5, e10100 (2010)CrossRef V. Salomaa, A. Havulinna, O. Saarela, T. Zeller, P. Jousilahti, A. Jula, T. Muenzel, A. Aromaa, A. Evans, K. Kuulasmaa, S. Blankenberg, Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS ONE 5, e10100 (2010)CrossRef
20.
go back to reference S.G. Wannamethee, P. Welsh, O. Papacosta, L. Lennon, P.H. Whincup, N. Sattar, Copeptin, insulin resistance, and risk of incident diabetes in older men. J. Clin. Endocrinol. Metab. 100, 3332–3339 (2015)CrossRef S.G. Wannamethee, P. Welsh, O. Papacosta, L. Lennon, P.H. Whincup, N. Sattar, Copeptin, insulin resistance, and risk of incident diabetes in older men. J. Clin. Endocrinol. Metab. 100, 3332–3339 (2015)CrossRef
21.
go back to reference J.D. Veldhuis, A. Sharma, F. Roelfsema, Age-dependent and gender-dependent regulation of hypothalamic-adrenocorticotropic-adrenal axis. Endocrinol. Metab. Clin. North. Am. 42, 201–225 (2013)CrossRef J.D. Veldhuis, A. Sharma, F. Roelfsema, Age-dependent and gender-dependent regulation of hypothalamic-adrenocorticotropic-adrenal axis. Endocrinol. Metab. Clin. North. Am. 42, 201–225 (2013)CrossRef
22.
go back to reference A. Abbasi, E. Corpeleijn, E. Meijer, D. Postmus, R.T. Gansevoort, R.O. Gans, J. Struck, H.L. Hillege, R.P. Stolk, G. Navis, S.J. Bakker, Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia 55, 1963–1970 (2012)CrossRef A. Abbasi, E. Corpeleijn, E. Meijer, D. Postmus, R.T. Gansevoort, R.O. Gans, J. Struck, H.L. Hillege, R.P. Stolk, G. Navis, S.J. Bakker, Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia 55, 1963–1970 (2012)CrossRef
23.
go back to reference N.S. Stachenfeld, A.E. Splenser, W.L. Calzone, M.P. Taylor, D.L. Keefe, Sex differences in osmotic regulation of AVP and renal sodium handling. J. Appl. Physiol. 91, 1893–1901 (1985)CrossRef N.S. Stachenfeld, A.E. Splenser, W.L. Calzone, M.P. Taylor, D.L. Keefe, Sex differences in osmotic regulation of AVP and renal sodium handling. J. Appl. Physiol. 91, 1893–1901 (1985)CrossRef
24.
go back to reference E. Kajantie, D.I. Phillips, The effects of sex and hormonal status on the physiological response to acute psychosocial stress. Psychoneuroendocrinology 31, 151–178 (2006)CrossRef E. Kajantie, D.I. Phillips, The effects of sex and hormonal status on the physiological response to acute psychosocial stress. Psychoneuroendocrinology 31, 151–178 (2006)CrossRef
25.
go back to reference W.R. Skowsky, L. Swan, P. Smith, Effects of sex steroid hormones on arginine vasopressin in intact and castrated male and female rats. Endocrinology 104, 105–108 (1979)CrossRef W.R. Skowsky, L. Swan, P. Smith, Effects of sex steroid hormones on arginine vasopressin in intact and castrated male and female rats. Endocrinology 104, 105–108 (1979)CrossRef
26.
go back to reference J.T. Crofton, P.G. Baer, L. Share, D.P. Brooks, Vasopressin release in male and female rats: Effects of gonadectomy and treatment with gonadal steroid hormones. Endocrinology 117, 1195–1200 (1985)CrossRef J.T. Crofton, P.G. Baer, L. Share, D.P. Brooks, Vasopressin release in male and female rats: Effects of gonadectomy and treatment with gonadal steroid hormones. Endocrinology 117, 1195–1200 (1985)CrossRef
27.
go back to reference N.S. Stachenfeld, L. DiPietro, C.A. Kokoszka, C. Silva, D.L. Keefe, E.R. Nadel, Physiological variability of fluid-regulation hormones in young women. J. Appl. Physiol. 86, 1092–1096 (1999)CrossRef N.S. Stachenfeld, L. DiPietro, C.A. Kokoszka, C. Silva, D.L. Keefe, E.R. Nadel, Physiological variability of fluid-regulation hormones in young women. J. Appl. Physiol. 86, 1092–1096 (1999)CrossRef
28.
go back to reference W.F. Trigoso, J.M. Wesly, D.L. Meranda, Y. Shenker, Vasopressin and atrial natriuretic hormone response to hypertonic saline during the follicular and luteal phases of the menstrual cycle. Hum. Reprod. 11, 2392–2395 (1996)CrossRef W.F. Trigoso, J.M. Wesly, D.L. Meranda, Y. Shenker, Vasopressin and atrial natriuretic hormone response to hypertonic saline during the follicular and luteal phases of the menstrual cycle. Hum. Reprod. 11, 2392–2395 (1996)CrossRef
29.
go back to reference T.J. Vokes, N.M. Weiss, J. Schreiber, M.B. Gaskill, G.L. Robertson, Osmoregulation of thirst and vasopressin during normal menstrual cycle. Am. J. Physiol. 254, R641–R647 (1988)PubMed T.J. Vokes, N.M. Weiss, J. Schreiber, M.B. Gaskill, G.L. Robertson, Osmoregulation of thirst and vasopressin during normal menstrual cycle. Am. J. Physiol. 254, R641–R647 (1988)PubMed
30.
go back to reference T.D.M. Williams, A. Edwards, K.M. Fairhall, I.C.A.F. Robinson, G.M. McGarrick, S.L. Lightman, Influence of endogenous and exogenous oestrogens on posterior pituitary secretion in women. Clin. Endocrinol. (Oxf.) 22, 589–596 (1985)CrossRef T.D.M. Williams, A. Edwards, K.M. Fairhall, I.C.A.F. Robinson, G.M. McGarrick, S.L. Lightman, Influence of endogenous and exogenous oestrogens on posterior pituitary secretion in women. Clin. Endocrinol. (Oxf.) 22, 589–596 (1985)CrossRef
31.
go back to reference M.I. Taskin, E. Bulbul, E. Adali, A.A. Hismiogulları, U. Inceboz, Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 189, 19–23 (2015)CrossRef M.I. Taskin, E. Bulbul, E. Adali, A.A. Hismiogulları, U. Inceboz, Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 189, 19–23 (2015)CrossRef
32.
go back to reference L. Bankir, P. Bardoux, M. Ahloulay, Vasopressin and diabetes mellitus. Nephron 87, 8–18 (2001)CrossRef L. Bankir, P. Bardoux, M. Ahloulay, Vasopressin and diabetes mellitus. Nephron 87, 8–18 (2001)CrossRef
33.
go back to reference M. Bustamante, U. Hasler, O. Kotova, A.V. Chibalin, D. Mordasini, M. Rousselot, A. Vandewalle, P.Y. Martin, E. Féraille, Insulin potentiates AVP-induced AQP2 expression in cultured renal collecting duct principal cells. Am. J. Physiol. Ren. Physiol. 288, F334–F344 (2005)CrossRef M. Bustamante, U. Hasler, O. Kotova, A.V. Chibalin, D. Mordasini, M. Rousselot, A. Vandewalle, P.Y. Martin, E. Féraille, Insulin potentiates AVP-induced AQP2 expression in cultured renal collecting duct principal cells. Am. J. Physiol. Ren. Physiol. 288, F334–F344 (2005)CrossRef
34.
go back to reference R. Roussel, R. El Boustany, N. Bouby, L. Potier, F. Fumeron, K. Mohammedi, B. Balkau, J. Tichet, L. Bankir, M. Marre, G. Velho, Plasma copeptin, AVP gene variants, and incidence of type 2 diabetes in a cohort from the community. J. Clin. Endocrinol. Metab. 101, 2432–2439 (2016)CrossRef R. Roussel, R. El Boustany, N. Bouby, L. Potier, F. Fumeron, K. Mohammedi, B. Balkau, J. Tichet, L. Bankir, M. Marre, G. Velho, Plasma copeptin, AVP gene variants, and incidence of type 2 diabetes in a cohort from the community. J. Clin. Endocrinol. Metab. 101, 2432–2439 (2016)CrossRef
35.
go back to reference C. Taveau, C. Chollet, L. Waeckel, D. Desposito, D.G. Bichet, M.F. Arthus, C. Magnan, E. Philippe, V. Paradis, F. Foufelle, I. Hainault, S. Enhorning, G. Velho, R. Roussel, L. Bankir, O. Melander, N. Bouby, Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats. Diabetologia 58, 1081–1090 (2015)CrossRef C. Taveau, C. Chollet, L. Waeckel, D. Desposito, D.G. Bichet, M.F. Arthus, C. Magnan, E. Philippe, V. Paradis, F. Foufelle, I. Hainault, S. Enhorning, G. Velho, R. Roussel, L. Bankir, O. Melander, N. Bouby, Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats. Diabetologia 58, 1081–1090 (2015)CrossRef
36.
go back to reference C.B. Wang, M. Zong, S.Q. Lu, Z. Tian, Plasma copeptin and functional outcome in patients with ischemic stroke and type 2 diabetes. J. Diabetes Complicat. 30, 1532–1536 (2016)CrossRef C.B. Wang, M. Zong, S.Q. Lu, Z. Tian, Plasma copeptin and functional outcome in patients with ischemic stroke and type 2 diabetes. J. Diabetes Complicat. 30, 1532–1536 (2016)CrossRef
37.
go back to reference M.I. Smaradottir, V. Ritsinger, V. Gyberg, A. Norhammar, P. Näsman, L.G. Mellbin, Copeptin in patients with acute myocardial infarction and newly detected glucose abnormalities–A marker of increased stress susceptibility? A report from the Glucose in Acute Myocardial Infarction cohort. Diab. Vasc. Dis. Res. 14, 69–76 (2017)CrossRef M.I. Smaradottir, V. Ritsinger, V. Gyberg, A. Norhammar, P. Näsman, L.G. Mellbin, Copeptin in patients with acute myocardial infarction and newly detected glucose abnormalities–A marker of increased stress susceptibility? A report from the Glucose in Acute Myocardial Infarction cohort. Diab. Vasc. Dis. Res. 14, 69–76 (2017)CrossRef
38.
go back to reference L.G. Mellbin, L. Rydén, K. Brismar, N.G. Morgenthaler, J. Ohrvik, S.B. Catrina, Copeptin, IGFBP-1, and cardiovascular prognosis in patients with type 2 diabetes and acute myocardial infarction: a report from the DIGAMI 2 trial. Diabetes Care 33, 1604–1606 (2010)CrossRef L.G. Mellbin, L. Rydén, K. Brismar, N.G. Morgenthaler, J. Ohrvik, S.B. Catrina, Copeptin, IGFBP-1, and cardiovascular prognosis in patients with type 2 diabetes and acute myocardial infarction: a report from the DIGAMI 2 trial. Diabetes Care 33, 1604–1606 (2010)CrossRef
39.
go back to reference S. Enhörning, B. Hedblad, P.M. Nilsson, G. Engström, O. Melander, Copeptin is an independent predictor of diabetic heart disease and death. Am. Heart J. 169, 546–556 (2015)CrossRef S. Enhörning, B. Hedblad, P.M. Nilsson, G. Engström, O. Melander, Copeptin is an independent predictor of diabetic heart disease and death. Am. Heart J. 169, 546–556 (2015)CrossRef
40.
go back to reference D. Bar-Shalom, M.K. Poulsen, L.M. Rasmussen, A.C. Diederichsen, N.P. Sand, J.E. Henriksen, M. Nybo, Plasma copeptin as marker of cardiovascular disease in asymptomatic type 2 diabetes patients. Diab. Vasc. Dis. Res. 11, 448–450 (2014)CrossRef D. Bar-Shalom, M.K. Poulsen, L.M. Rasmussen, A.C. Diederichsen, N.P. Sand, J.E. Henriksen, M. Nybo, Plasma copeptin as marker of cardiovascular disease in asymptomatic type 2 diabetes patients. Diab. Vasc. Dis. Res. 11, 448–450 (2014)CrossRef
41.
go back to reference M. Thibonnier, M.K. Graves, M.S. Wagner, N. Chatelain, F. Soubrier, P. Corvol, H.F. Willard, X. Jeunemaitre, Study of V(1)-vascular vasopressin receptor gene microsatellite polymorphisms in human essential hypertension. J. Mol. Cell. Cardiol. 32, 557–564 (2000)CrossRef M. Thibonnier, M.K. Graves, M.S. Wagner, N. Chatelain, F. Soubrier, P. Corvol, H.F. Willard, X. Jeunemaitre, Study of V(1)-vascular vasopressin receptor gene microsatellite polymorphisms in human essential hypertension. J. Mol. Cell. Cardiol. 32, 557–564 (2000)CrossRef
42.
go back to reference P. Bjornstad, D.M. Maahs, T. Jensen, M.A. Lanaspa, R.J. Johnson, M. Rewers, J.K. Snell-Bergeon, Elevated copeptin is associated with atherosclerosis and diabetic kidney disease in adults with type 1 diabetes. J. Diabetes Complicat. 30, 1093–1096 (2016)CrossRef P. Bjornstad, D.M. Maahs, T. Jensen, M.A. Lanaspa, R.J. Johnson, M. Rewers, J.K. Snell-Bergeon, Elevated copeptin is associated with atherosclerosis and diabetic kidney disease in adults with type 1 diabetes. J. Diabetes Complicat. 30, 1093–1096 (2016)CrossRef
43.
go back to reference W.E. Boertien, I.J. Riphagen, I. Drion, A. Alkhalaf, S.J. Bakker, K.H. Groenier, R.T. Gansevoort, Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33). Diabetologia 56, 1680–1688 (2013)CrossRef W.E. Boertien, I.J. Riphagen, I. Drion, A. Alkhalaf, S.J. Bakker, K.H. Groenier, R.T. Gansevoort, Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33). Diabetologia 56, 1680–1688 (2013)CrossRef
44.
go back to reference M. Pikkemaat, O. Melander, K. Bengtsson Boström, Association between copeptin and declining glomerular filtration rate in people with newly diagnosed diabetes. The Skaraborg Diabetes Register. J. Diabetes Complicat. 26, 1062–1065 (2015)CrossRef M. Pikkemaat, O. Melander, K. Bengtsson Boström, Association between copeptin and declining glomerular filtration rate in people with newly diagnosed diabetes. The Skaraborg Diabetes Register. J. Diabetes Complicat. 26, 1062–1065 (2015)CrossRef
45.
go back to reference G. Velho, R. El Boustany, G. Lefèvre, K. Mohammedi, F. Fumeron, L. Potier, L. Bankir, N. Bouby, S. Hadjadj, M. Marre, R. Roussel, Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. Diabetes Care 36, 3639–3645 (2013)CrossRef G. Velho, R. El Boustany, G. Lefèvre, K. Mohammedi, F. Fumeron, L. Potier, L. Bankir, N. Bouby, S. Hadjadj, M. Marre, R. Roussel, Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. Diabetes Care 36, 3639–3645 (2013)CrossRef
46.
go back to reference P. Bardoux, D.G. Bichet, H. Martin, Y. Gallois, M. Marre, M.F. Arthus, M. Lonergan, N. Ruel, N. Bouby, L. Bankir, Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system. Nephrol. Dial. Transplant. 18, 497–506 (2003)CrossRef P. Bardoux, D.G. Bichet, H. Martin, Y. Gallois, M. Marre, M.F. Arthus, M. Lonergan, N. Ruel, N. Bouby, L. Bankir, Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system. Nephrol. Dial. Transplant. 18, 497–506 (2003)CrossRef
47.
go back to reference P. Bardoux, P. Bruneval, D. heudes, N. Bouby, L. Bankir, Diabetes-induced albuminuria: role of antidiuretic hormone as a revealed by chronic V2 receptor antagonism in rats. Nephrol. Dial. Transplant. 18, 1755–1763 (2003)CrossRef P. Bardoux, P. Bruneval, D. heudes, N. Bouby, L. Bankir, Diabetes-induced albuminuria: role of antidiuretic hormone as a revealed by chronic V2 receptor antagonism in rats. Nephrol. Dial. Transplant. 18, 1755–1763 (2003)CrossRef
48.
go back to reference E. Perrier, S. Vergne, A. Klein, M. Poupin, P. Rondeau, L. Le Bellego, L.E. Armstrong, F. Lang, J. Stookey, I. Tack, Hydration biomarkers in free-living adults with different levels of habitual fluid consumption. Br. J. Nutr. 109, 1678–1687 (2013)CrossRef E. Perrier, S. Vergne, A. Klein, M. Poupin, P. Rondeau, L. Le Bellego, L.E. Armstrong, F. Lang, J. Stookey, I. Tack, Hydration biomarkers in free-living adults with different levels of habitual fluid consumption. Br. J. Nutr. 109, 1678–1687 (2013)CrossRef
49.
go back to reference A. Tanoue, S. Ito, K. Honda, S. Oshikawa, Y. Kitagawa, T.A. Koshimizu, T. Mori, G. Tsujimoto, The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J. Clin. Invest. 113, 302–309 (2004)CrossRef A. Tanoue, S. Ito, K. Honda, S. Oshikawa, Y. Kitagawa, T.A. Koshimizu, T. Mori, G. Tsujimoto, The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J. Clin. Invest. 113, 302–309 (2004)CrossRef
50.
go back to reference I. Tatsuno, D. Uchida, T. Tanaka, H. Koide, A. Shigeta, T. Ichikawa, H. Sasano, Y. Saito, Vasopressin responsiveness of subclinical Cushing’s syndrome due to ACTH-independent macronodular adrenocortical hyperplasia. Clin. Endocrinol. (Oxf.). 60, 192–200 (2004)CrossRef I. Tatsuno, D. Uchida, T. Tanaka, H. Koide, A. Shigeta, T. Ichikawa, H. Sasano, Y. Saito, Vasopressin responsiveness of subclinical Cushing’s syndrome due to ACTH-independent macronodular adrenocortical hyperplasia. Clin. Endocrinol. (Oxf.). 60, 192–200 (2004)CrossRef
51.
go back to reference J. Hensen, O. Hader, V. Bähr, W. Oelkers, Effects of incremental infusions of arginine vasopressin on adrenocorticotropin and cortisol secretion in man. J. Clin. Endocrinol. Metab. 66, 668–671 (1988)CrossRef J. Hensen, O. Hader, V. Bähr, W. Oelkers, Effects of incremental infusions of arginine vasopressin on adrenocorticotropin and cortisol secretion in man. J. Clin. Endocrinol. Metab. 66, 668–671 (1988)CrossRef
52.
go back to reference C. Rabadan-Diehl, G. Aguilera, Glucocorticoids increase vasopressin V1b receptor coupling to phospholipase C. Endocrinology 139, 3220–3226 (1998)CrossRef C. Rabadan-Diehl, G. Aguilera, Glucocorticoids increase vasopressin V1b receptor coupling to phospholipase C. Endocrinology 139, 3220–3226 (1998)CrossRef
53.
go back to reference G.L. Firestone, J.R. Giampaolo, B.A. O’Keeffe, Stimulus-dependent regulation of serum and glucocorticoid inducible protein kinase (SGK) transcription, subcellular localization and enzymatic activity. Cell. Physiol. Biochem. 13, 1–12 (2003)CrossRef G.L. Firestone, J.R. Giampaolo, B.A. O’Keeffe, Stimulus-dependent regulation of serum and glucocorticoid inducible protein kinase (SGK) transcription, subcellular localization and enzymatic activity. Cell. Physiol. Biochem. 13, 1–12 (2003)CrossRef
54.
go back to reference F. Lang, A. Görlach, V. Vallon, Targeting SGK1 in diabetes. Expert Opin. Ther. Targets 13, 1303–1311 (2009)CrossRef F. Lang, A. Görlach, V. Vallon, Targeting SGK1 in diabetes. Expert Opin. Ther. Targets 13, 1303–1311 (2009)CrossRef
55.
go back to reference F. Lang, C. Böhmer, M. Palmada, G. Seebohm, N. Strutz-Seebohm, V. Vallon, (Patho)physiological significance of the serum-and glucocorticoid-inducible kinase isoform. Physiol. Rev. 86, 1151–1178 (2006)CrossRef F. Lang, C. Böhmer, M. Palmada, G. Seebohm, N. Strutz-Seebohm, V. Vallon, (Patho)physiological significance of the serum-and glucocorticoid-inducible kinase isoform. Physiol. Rev. 86, 1151–1178 (2006)CrossRef
56.
go back to reference N. Di Pietro, V. Panel, S. Hayes, A. Bagattin, S. Meruvu, A. Pandolfi, L. Hugendubler, G. Fejes-Tóth, A. Naray-Fejes-Tóth, E. Mueller, Serum-and glucocorticoid-inducible kinase 1 (SGK1) regulates adipocyte differentiation via forkhead box O1. Mol. Endocrinol. 24, 370–380 (2010)CrossRef N. Di Pietro, V. Panel, S. Hayes, A. Bagattin, S. Meruvu, A. Pandolfi, L. Hugendubler, G. Fejes-Tóth, A. Naray-Fejes-Tóth, E. Mueller, Serum-and glucocorticoid-inducible kinase 1 (SGK1) regulates adipocyte differentiation via forkhead box O1. Mol. Endocrinol. 24, 370–380 (2010)CrossRef
57.
go back to reference L. Lecavalier, G. Bolli, J. Gerich, Glucagon-cortisol interactions on glucose turnover and lactate gluconeogenesis in normal humans. Am. J. Physiol. 258(4 Pt 1), E569–E575 (1990)PubMed L. Lecavalier, G. Bolli, J. Gerich, Glucagon-cortisol interactions on glucose turnover and lactate gluconeogenesis in normal humans. Am. J. Physiol. 258(4 Pt 1), E569–E575 (1990)PubMed
58.
go back to reference P.R. Bratusch-Marrain, R.A. DeFronzo, Impairment of insulin-mediated glucose metabolism by hyperosmolality in man. Diabetes 32, 1028–1034 (1983)CrossRef P.R. Bratusch-Marrain, R.A. DeFronzo, Impairment of insulin-mediated glucose metabolism by hyperosmolality in man. Diabetes 32, 1028–1034 (1983)CrossRef
59.
go back to reference A.M. O’Carroll, G.M. Howell, E.M. Roberts, S.J. Lolait, Vasopressin potentiates corticotropin-releasing hormone-induced insulin release from mouse pancreatic beta-cells. J. Endocrinol. 197, 231–239 (2008)CrossRef A.M. O’Carroll, G.M. Howell, E.M. Roberts, S.J. Lolait, Vasopressin potentiates corticotropin-releasing hormone-induced insulin release from mouse pancreatic beta-cells. J. Endocrinol. 197, 231–239 (2008)CrossRef
60.
go back to reference M. Lu, S.P. Soltoff, G.C. Yaney, A.E. Boyd 3rd, The mechanisms underlying the glucose dependence of arginine vasopressin-induced insulin secretion in beta-cells. Endocrinology 132, 2141–2148 (1993)CrossRef M. Lu, S.P. Soltoff, G.C. Yaney, A.E. Boyd 3rd, The mechanisms underlying the glucose dependence of arginine vasopressin-induced insulin secretion in beta-cells. Endocrinology 132, 2141–2148 (1993)CrossRef
61.
go back to reference M. Hiroyama, T. Aoyagi, Y. Fujiwara, J. Birumachi, Y. Shigematsu, K. Kiwaki, R. Tasaki, F. Endo, A. Tanoue, Hypermetabolism of fat in V1a vasopressin receptor knockout mice. Mol. Endocrinol. 21, 247–258 (2007)CrossRef M. Hiroyama, T. Aoyagi, Y. Fujiwara, J. Birumachi, Y. Shigematsu, K. Kiwaki, R. Tasaki, F. Endo, A. Tanoue, Hypermetabolism of fat in V1a vasopressin receptor knockout mice. Mol. Endocrinol. 21, 247–258 (2007)CrossRef
62.
go back to reference Y. Fujiwara, M. Hiroyama, A. Sanbe, J. Yamauchi, G. Tsujimoto, A. Tanoue, Mutual regulation of vasopressin- and oxytocin-induced glucagon secretion in V1b vasopressin receptor knockout mice. J. Endocrinol. 192, 361–369 (2007)CrossRef Y. Fujiwara, M. Hiroyama, A. Sanbe, J. Yamauchi, G. Tsujimoto, A. Tanoue, Mutual regulation of vasopressin- and oxytocin-induced glucagon secretion in V1b vasopressin receptor knockout mice. J. Endocrinol. 192, 361–369 (2007)CrossRef
63.
go back to reference S. Masuki, M. Mori, Y. Tabara, T. Miki, A. Sakurai, M. Morikawa, K. Miyagawa, K. Higuchi, H. Nose, Shinshu University Genetic Research Consortium Vasopressin V1a receptor polymorphism and interval walking training effects in middle-aged and older people. Hypertension 55, 747–754 (2010)CrossRef S. Masuki, M. Mori, Y. Tabara, T. Miki, A. Sakurai, M. Morikawa, K. Miyagawa, K. Higuchi, H. Nose, Shinshu University Genetic Research Consortium Vasopressin V1a receptor polymorphism and interval walking training effects in middle-aged and older people. Hypertension 55, 747–754 (2010)CrossRef
64.
go back to reference S. Enhörning, M. Leosdottir, P. Wallström, B. Gullberg, G. Berglund, E. Wirfält, O. Melander, Relation between human vasopressin 1a gene variance, fat intake, and diabetes. Am. J. Clin. Nutr. 89, 400–406 (2009)CrossRef S. Enhörning, M. Leosdottir, P. Wallström, B. Gullberg, G. Berglund, E. Wirfält, O. Melander, Relation between human vasopressin 1a gene variance, fat intake, and diabetes. Am. J. Clin. Nutr. 89, 400–406 (2009)CrossRef
65.
go back to reference L. Bankir, S. Fernandes, P. Bardoux, N. Bouby, D.G. Bichet, Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans. J. Am. Soc. Nephrol. 16, 1920–1928 (2005)CrossRef L. Bankir, S. Fernandes, P. Bardoux, N. Bouby, D.G. Bichet, Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans. J. Am. Soc. Nephrol. 16, 1920–1928 (2005)CrossRef
66.
go back to reference P. Bardoux, H. Martin, M. Ahloulay, F. Schmitt, N. Bouby, M.M. Trinh-Trang-Tan, L. Bankir, Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats. Proc. Natl Acad. Sci. USA 96, 10397–10402 (1999)CrossRef P. Bardoux, H. Martin, M. Ahloulay, F. Schmitt, N. Bouby, M.M. Trinh-Trang-Tan, L. Bankir, Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats. Proc. Natl Acad. Sci. USA 96, 10397–10402 (1999)CrossRef
67.
go back to reference N. Bouby, S. Bachmann, D. Bichet, L. Bankir, Effects of water on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am. J. Physiol. 258, F979–F979 (1990) N. Bouby, S. Bachmann, D. Bichet, L. Bankir, Effects of water on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am. J. Physiol. 258, F979–F979 (1990)
68.
go back to reference T. Sugiura, A. Yamauchi, H. Kitamura, Y. Matsuoka, M. Horio, E. Imai, M. Hori, High water intake ameliorates tubulointerstitial injury in rats with subtotal nephrectomy: possible role of TGF-beta. Kidney Int. 55, 1800–1810 (1999)CrossRef T. Sugiura, A. Yamauchi, H. Kitamura, Y. Matsuoka, M. Horio, E. Imai, M. Hori, High water intake ameliorates tubulointerstitial injury in rats with subtotal nephrectomy: possible role of TGF-beta. Kidney Int. 55, 1800–1810 (1999)CrossRef
69.
go back to reference W. Fenske, C. Wanner, B. Allolio, C. Drechsler, K. Blouin, J. Lilienthal, V. Krane, German Diabetes, Dialysis Study Investigators Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. J. Am. Soc. Nephrol. 22, 782–790 (2011)CrossRef W. Fenske, C. Wanner, B. Allolio, C. Drechsler, K. Blouin, J. Lilienthal, V. Krane, German Diabetes, Dialysis Study Investigators Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. J. Am. Soc. Nephrol. 22, 782–790 (2011)CrossRef
70.
go back to reference M.F. Maturi, S.E. Martin, D. Markle, M. Maxwell, C.R. Burruss, E. Speir, R. Greene, Y.M. Ro, D. Vitale, M.V. Green, Coronary vasoconstriction induced by vasopressin. Production of 470 myocardial ischemia in dods by constriction of nondiseased small vessels. Circulation 83, 2111–2121 (1991)CrossRef M.F. Maturi, S.E. Martin, D. Markle, M. Maxwell, C.R. Burruss, E. Speir, R. Greene, Y.M. Ro, D. Vitale, M.V. Green, Coronary vasoconstriction induced by vasopressin. Production of 470 myocardial ischemia in dods by constriction of nondiseased small vessels. Circulation 83, 2111–2121 (1991)CrossRef
71.
go back to reference J. Fukuzawa, T. Haneda, K. Kikuchi, Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol. Cell. Biochem. 195, 93–98 (1999)CrossRef J. Fukuzawa, T. Haneda, K. Kikuchi, Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol. Cell. Biochem. 195, 93–98 (1999)CrossRef
Metadata
Title
Water intake keeps type 2 diabetes away? Focus on copeptin
Authors
Giovanna Muscogiuri
Luigi Barrea
Giuseppe Annunziata
Martina Vecchiarini
Francesco Orio
Carolina Di Somma
Annamaria Colao
Silvia Savastano
Publication date
01-11-2018
Publisher
Springer US
Published in
Endocrine / Issue 2/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-018-1680-7

Other articles of this Issue 2/2018

Endocrine 2/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.